HEFCE closed at the end of March 2018. The information on this website is historical and is no longer maintained.
The HEFCE domain - www.hefce.ac.uk - will continue to function until September 2018. At this point we will close the site entirely and all its information will only be available from the National Web Archive.
The institute will bring together multi-disciplinary teams of scientists, academic clinicians, clinical trial specialists and nurses. These teams will aim to:
To consolidate the strength of its research, the institute will partner with another biomedical research centre - the Francis Crick Institute. Working with other university partners will also provide access to a patient population of six million.
State-of-the-art research labs, equipment and clinical-trial facilities will allow researchers to rapidly adapt their research methods to produce therapeutics for trial with patients.
The institute will work with industry and the technology and innovation centre, Cell Therapy Catapult. This will help to increase the scale of the institute’s work and develop new forms of tissue, cell and gene therapy for the benefit of patients.
Phase I of the Institute, comprising 18002m of refurbished space, opened in June 2013. A new institute building will be completed in 2017, and will provide space for 20-25 research groups, each with 8-10 researchers.
|Name||Professor Hans Stauss|
|Title||Director of the Institute of Immunity & Transplantation|
|Tel||0207 794 0500 x33321|
Page last updated 26 February 2015